Back
Compare AU
Compare DRUG vs. 30BB
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Betashares 2030 Fixed Term Corp Bond Active ETF (30BB). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | 30BB | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 73 | 3 |
Median incremental investment | $740.50 | $10,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,623.50 | $9,717.00 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | 30BB | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | 30BB.AX was created on 2025-04-30 by BetaShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The Fund aims to provide investors with access to a diversified portfolio of fixed-rate, investment grade, Australian dollar denominated corporate bonds with maturity dates occurring between May 2029 and May 2030. |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | TOYOTA FINANCE AUSTRALIA 5.2% JAN-30 (4.03 %) VERIZON COMMUNICATIONS 2.65% MAY-30 (3.82 %) STOCKLAND TRUST 5.45% APR-30 (3.57 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | |
Management fee | 0.57 % | 0 % |
Key Summary
DRUG | 30BB | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0 % |
Price | $8.50 | $24.60 |
Size | $176.672 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 2.00 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 01/05/2025 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | 30BB | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 73 | 3 |
Median incremental investment | $740.50 | $10,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,623.50 | $9,717.00 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | 30BB | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | 30BB |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |